September 10, 2025Lab on a ChipOpen Access

Evaluating Caplacizumab’s Potential to Mitigate Thrombosis Risk in Aortic Valve Stenosis: A Microfluidic and Computational Approach

View Full Paper

Ask AI

Bookmark

Caplacizumab reduced platelet coverage by up to 90% in high shear conditions, indicating strong anti-thrombotic effects.
Microfluidic experiments revealed that increased shear gradients exacerbate platelet aggregation with stenosis severity.
Using computational fluid dynamics, the study simulated hemodynamic conditions in aortic valve stenosis to assess treatment impact.
Findings suggest potential for caplacizumab as a less invasive alternative for managing thrombotic risk in aortic valve stenosis.

Discussion

No takes yet. Share an insight, caveat, or question.

This analysis shows caplacizumab significantly reduces thrombosis risk in aortic valve stenosis, suggesting innovative treatment strategies.

Shirejini et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This analysis shows caplacizumab significantly reduces thrombosis risk in aortic valve stenosis, suggesting innovative treatment strategies.